We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Blocking Activity of Glucagon Hormone Could Treat Common and Challenging Type of Heart Failure

By HospiMedica International staff writers
Posted on 01 Oct 2024

Globally, approximately 64 million people suffer from heart failure, which has become a global pandemic. More...

Heart failure with preserved ejection fraction (HFpEF), a particularly challenging form of heart failure to treat, accounts for about half of these cases. In heart failure, the heart is unable to pump blood effectively. In HFpEF, the heart can pump normally, but its muscles are too stiff to relax and properly fill the chambers with blood. HFpEF often affects older adults and individuals with multiple risk factors such as high blood pressure, obesity, and diabetes. Patients with HFpEF typically experience symptoms like shortness of breath, fatigue, and reduced exercise capacity. This differs from heart failure with reduced ejection fraction (HFrEF), where the heart muscle is weakened and cannot pump with sufficient force, leading to a reduced amount of blood being circulated. Although there have been studies on how hypertension and obesity-related metabolic diseases, such as diabetes, stress the heart, these conditions have generally been studied in isolation.

Now, scientists at Duke-NUS Medical School (Singapore) and their collaborators have now identified a potential new treatment for HFpEF. The team discovered elevated levels of glucagon activity—a hormone produced by the pancreas that raises blood sugar—in the diseased heart cells. Building on this insight, they demonstrated that a drug capable of blocking this hormone could significantly improve heart function. This groundbreaking study, published in Circulation Research, considered both hypertension and obesity-associated metabolic diseases and revealed, for the first time, a molecular pathway contributing to HFpEF progression. In preclinical studies, the researchers examined the effects of hypertension on lean and diabetic/obese hearts. They found that hypertension led to HFrEF in lean models, a condition typically observed in hypertensive patients. However, obese models developed HFpEF, suggesting that a combination of stressors triggers the disease, providing a useful model for further research.

Using advanced single-cell RNA sequencing, the scientists were able to analyze the expression of every gene detected in individual heart cells, uncovering specific genetic variations linked to HFpEF. They discovered that in obese models, the most active genes were those driving glucagon activity. Under conditions of high blood pressure and metabolic disorders like obesity and diabetes, glucagon signaling in heart cells becomes excessively active. This overactivity contributes to HFpEF by increasing heart stiffness and reducing its ability to relax and fill with blood.

The team then tested a drug that blocks the glucagon receptor in a pre-clinical HFpEF model and observed significant improvements in heart function. These improvements included reduced heart stiffness, enhanced relaxation, better blood-filling capacity, and overall improved heart performance. The researchers now aim to collaborate with clinical partners to conduct trials testing the glucagon receptor blocker in humans with HFpEF. If successful, this treatment could become one of the first effective therapies for this difficult condition, improving the quality of life for millions worldwide.

“With our aging population, there will likely be more patients with multiple conditions, including heart failure, diabetes, and hypertension, presenting a significant challenge to health systems,” said Professor Patrick Tan, Senior Vice-Dean for Research at Duke-NUS. “Uncovering the synergistic impact of such illnesses and their underlying mechanisms is key to better understanding the complex process of heart failure and developing an effective treatment for the disease.”


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
12-Channel ECG
CM1200B
New
Trocar
TAN RoTaLock Trocar
New
Instrument Cabinet
TRZY-068
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: For the first time, a fluorescent-guided nerve imaging agent has shown promise for use in humans (Photo courtesy of VUMC)

Fluorescent Imaging Agent ‘Lights Up’ Nerves for Better Visualization During Surgery

Surgical nerve injury is a significant concern in head and neck surgeries, where nerves are at risk of being inadvertently damaged during procedures. Such injuries can lead to complications that may impact... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.